Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.

Despite the highly significant therapeutic relevance of combinatorial therapy ( Conway and Cohen, 2010 ; Morphy, 2010 ; Wright, 2010 ; Modi et al., 2011 ; Lu et al., 2012 ), single MTA has substantial advantages over combination therapy: 1) more predictable pharmacokinetic profile 2) avoiding drug-drug interactions 3) easier dose regimen and higher compliance 4) enabling to overcome mutations in relevant diseases such as cancer, viral and bacterial ailments 5) simultaneous presence of the molecule in tissues where it is expected to affect and 6) an easier regulatory process ( Hopkins, 2008 ; Anighoro et al., 2014 ).

also in 132,142 other papers